de Paula Hidyanara L, de Souza Carlos D F, Silva Sara R, Martins-Filho Paulo R S, Barreto Josafá G, Gurgel Ricardo Q, Cuevas Luis E, Santos Victor S
Centre for Epidemiology and Public Health, Federal University of Alagoas, Arapiraca, Alagoas, Brazil.
Investigative Pathology Laboratory, Federal University of Sergipe, Aracaju, Sergipe, Brazil.
JAMA Dermatol. 2019 Oct 1;155(10):1120-1128. doi: 10.1001/jamadermatol.2019.1768.
The World Health Organization (WHO) 2016-2020 Global Leprosy Strategy aims to reinvigorate efforts to control leprosy and avert leprosy disability to less than 1 per million population.
To systematically identify clinical factors associated with physical disability in patients with leprosy.
Searches were conducted in Scopus, PubMed, and Web of Science databases to identify studies published from January 23, 1988, to May 23, 2018, using the keywords leprosy and physical disability and related terms.
Studies that evaluated patients using the WHO leprosy disability grading system and reported the number of patients with and without disability by clinical characteristics were included.
The odds ratio (OR) was used as a measure of association between the clinical features and physical disability. Summary estimates were calculated using random-effects models.
The primary outcome was physical disability according to the WHO disability classification. The association between clinical features and physical disability was evaluated.
The search identified 2447 reports. After screening titles and abstracts, 177 full-text articles were assessed for eligibility, and 32 studies were included in the systematic review; 24 of the 32 studies included sex information (39 571 patients), of whom 24 218 (61.2%) were male. Male patients with leprosy were more likely to have physical disability than female patients with leprosy (pooled OR, 1.66; 95% CI, 1.43-1.93; I2, 81.3%; P < .001). Persons with multibacillary leprosy were 4-fold more likely to have physical disability than those with paucibacillary leprosy (pooled OR, 4.32; 95% CI, 3.37-5.53; I2, 88.9%, P < .001). Patients having leprosy reactions were more likely to have disability (pooled OR, 2.43; 95% CI, 1.35-4.36; I2, 92.1%; P < .001). Patients with lepromatous leprosy experienced 5- to 12-fold higher odds of disability.
This systematic review and meta-analysis confirms the association between the presence of physical disabilities and male sex, multibacillary leprosy, leprosy reactions, and lepromatous presentation. These findings can guide the development of targeted interventions for early identification of individuals at greater risk of developing physical disabilities and education campaigns to promote early consultation to institute treatment for leprosy reactions and prevent physical disability.
世界卫生组织(WHO)2016 - 2020年全球麻风病战略旨在重振控制麻风病的努力,并将麻风病致残率降低至每百万人口低于1例。
系统识别麻风病患者身体残疾相关的临床因素。
在Scopus、PubMed和Web of Science数据库中进行检索,以识别1988年1月23日至2018年5月23日发表的研究,使用关键词“麻风病”和“身体残疾”以及相关术语。
纳入使用WHO麻风病残疾分级系统评估患者,并按临床特征报告有残疾和无残疾患者数量的研究。
比值比(OR)用作临床特征与身体残疾之间关联的度量。使用随机效应模型计算汇总估计值。
主要结局是根据WHO残疾分类的身体残疾情况。评估临床特征与身体残疾之间的关联。
检索到2447篇报告。在筛选标题和摘要后,对177篇全文文章进行了资格评估,32项研究纳入系统评价;32项研究中的24项纳入了性别信息(39571例患者),其中24218例(61.2%)为男性。麻风病男性患者比女性患者更易出现身体残疾(合并OR,1.66;95%CI,1.43 - 1.93;I²,81.3%;P <.001)。多菌型麻风病患者出现身体残疾的可能性是少菌型麻风病患者的4倍(合并OR,4.32;95%CI,3.37 - 5.53;I²,88.9%,P <.001)。有麻风病反应的患者更易出现残疾(合并OR,2.43;95%CI,1.35 - 4.36;I²,92.1%;P <.001)。瘤型麻风病患者出现残疾的几率高5至12倍。
本系统评价和荟萃分析证实了身体残疾与男性、多菌型麻风病、麻风病反应及瘤型表现之间的关联。这些发现可指导制定有针对性的干预措施,以早期识别身体残疾风险较高的个体,并开展教育活动,促进早期咨询,以便对麻风病反应进行治疗并预防身体残疾。